期刊文献+

非小细胞肺癌组织硫氧还蛋白还原酶表达及预后分析 被引量:5

Expression and prognosis of TrxR in non-small cell lung cancer tissues
原文传递
导出
摘要 目的 硫氧还蛋白还原酶(thioredoxin reductase,TrxR)是肿瘤相关性蛋白,其在肿瘤细胞的增殖和分化中起着重要的作用。本研究探讨TrxR在非小细胞肺癌(non-small cell lung cancer,NSCLC)中的表达及对预后的影响。方法免疫组化法检测潍坊市人民医院胸外科2013-02-01-10-30 87例NSCLC组织和20例癌旁正常组织中TrxR的表达,分析其与临床病理参数之间的关系,并随访患者生存时间进行分析。结果肺癌组织TrxR阳性率为93.1%(81/87),癌旁组织中阳性率为20.0%(4/20),差异有统计学意义,χ^2=52.710,P〈0.01。低分化癌组织TrxR表达高于中、高分化癌组织,差异有统计学意义,χ^2=11.876,P=0.03。有淋巴结转移组TrxR表达高于无淋巴结转移组,差异有统计学意义,χ^2=5.471,P=0.02。TNM分期中Ⅲ~Ⅳ期TrxR的表达明显高于Ⅰ、Ⅱ期中的表达,差异有统计学意义,χ^2=4.711,P=0.03。TrxR的表达水平与患者的性别、年龄、吸烟史和病理分型无明显相关性。Kaplan-Meier生存分析结果显示,TrxR高表达组患者预后更差,χ^2=6.467,P=0.01。多因素Cox回归分析显示,TrxR是危险因素,P〈0.01。结论 TrxR在NSCLC中高表达并提示预后不良。 OBJECTIVE Thioredoxin reductase (TrxR) is a kind of protein which is associated with a novel tumor. It always plays an important role in the proliferation and differentiation of tumor cells. This paper aimed at studying the expression and prognosis of TrxR in non-small cell lung cancer (NSCLC). METHODS The sample sources in the test were from the Department of thoracic surgery of Weifang People's Hospital from February 1 to October 30 2013. Immunohistochemistry was used to detect the expression of TrxR in 87 NSCLC tissues and 20 adjacent lung tissues, and to analyze the relationship between clinical pathological features and the expression of TIXR. At the same time the survival time of the patients were acquired through the follow-up examination on patients. RESULTS The positive rate of TrxR was 93.1%(81/87) in NSCLC tissues and 20.0%(4/20) in non-malignant tissue section (χ^2=52. 710,P〈0.01). The positive rate of TrxR in poorly differentiated carcinoma tissues was higher than that in highly differentiated carcinoma tissues (χ^2 = 11. 876,P= 0. 03). TrxR expression was also significantly different between patients with or without lymph nodes metastasis (χ^2 = 5. 471,P= 0.02). The expression was correlated with tumor TNM staging. There was a significant difference of the TrxR expression between Ⅰ , Ⅱ and Ⅲ- Ⅳ stage cancerous tissues (χ^2 =4. 711 ,P=0.03). The patient' s gender, age, smoking history or pathological classification had no obvious correlation with the expression of TrxR. According to the follow up 87 patients, it was found that the prognosis of patients with TrxR high expression group was poor, (χ^2 = 6. 467, P = 0.01). CONCLUSION The expression of TrxR is higher in NSCLC and closely related to prognosis.
作者 张文利 孙开宇 谭强 刁秀芳 刘婷 ZHANG Wen-li SUN Kai-yu TAN Qiang DIAO Xiu- fang LIU Ting(Department of Respiratory Medicine, Wei fang People's Hospital, Weifang 261000,P. R. China)
出处 《中华肿瘤防治杂志》 CAS 北大核心 2016年第18期1224-1228,共5页 Chinese Journal of Cancer Prevention and Treatment
关键词 肺肿瘤 免疫组织化学 硫氧还蛋白还原酶 预后 lung neoplasms immunohistochemical thioredoxin reductase(TrxR) prognosis
  • 引文网络
  • 相关文献

参考文献3

二级参考文献12

  • 1Rajib Sengupta,Arne Holmgren.Thioredoxin and glutaredoxin-mediated redox regulation of ribonucleotide reductase[J].World Journal of Biological Chemistry,2014,5(1):68-74. 被引量:6
  • 2Feng X X,Sheng L L,Xi Y G,et al.The inhibitory effect of a novel organoselenium compound BBSKE on the tongue cancer Tca8113 in vitro and in vivo[J].Oral Oncol,2008,44:963-9.
  • 3Chang J S,Li Z Y,Feng G Y,et al.A novel organoselenium compound induces cell cycle arrest and apoptosis in prostate cancer cell lines[J].Biochem Biophys Res Commun,2003,309:578-83.
  • 4Scully C,Bagan J V.Recent advances in oral oncology 2008;squamous cell carcinoma imaging,treatment,prognostication and treatment outcomes[J].Oral Oncol,2009,45(6):e25-30.
  • 5Fang Z,Jun Y,Sheng J D.A thioredoxin reductase inhibitor induces growth inhibition and apoptosis in five cultured human carcinoma cell lines[J].Cancer Lett,2006,236:46-53.
  • 6Zhou H Y,Dou G F,Meng Z Y,et al.High performance liquid chromatographic determination of BBSKE,a novel organoselenium compound,in dog plasma using pre-column derivatization and its application in pharmacokinetic study[J].J Chromatography B,2007,852:617-24.
  • 7Zhou H Y,Dou G F,Meng Z Y,et al.Development of a rapid and sensitive liquid chromatography/tandem mass spectrometry method for the determination of 1,2-[bis(1,2-benzisoselenazolone-3(2H)-ketone)]-ethane (BBSKE),a novel anti-cancer agent in rat plasma[J].Biomed Chromatography,2008,22(10):1123-9.
  • 8Fischer H.Terlinden R,Lohr J P,Romer A.A novel biologically active selenoorangic compound.Ⅷ.Biotransformation of ebselen[J].Xenobiotica,1988,18(12),1347-59.
  • 9Kamigata N,Takata M,Matsuyama H,et al.Novel ring opening reaction of 2-aryl-1,2-benzisoselenazol-3(2H)-one with thiols[J].Heterocycles,1986,24:3027-30.
  • 10Ullrich V,Weber P,Meisch F,et al.Ebselen binding equilibria between plasma and target proteins[J].Biochem Pharmacol,1996,52:15-19.

共引文献1312

同被引文献48

引证文献5

二级引证文献30

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部